Vyriad
Latest round
- Series B
Last raised
- May 2022
Total raised
- $30M
Investors
- 4
About Vyriad
Based in Minnesota, US, and founded in 2015 by Stephen J. Russell (CEO), and Kah-Whye Peng (CTO), Vyriad, Inc. operates as a biotechnology company that provides clinical-stage developing oncolytic virus therapies to treat a wide range of cancers. In May 2022, Vyriad, Inc. In December 2025, Vyriad, Inc. Vyriad, Inc. is a diagnostic company that fights cancer cells, activates immune responses, and stops cancer recurrence. Furthermore, the company provides oncolytic virus therapies that use engineered viruses to target ovarian cancer, glioblastoma, mesothelioma, head and neck cancer, blood cancers, endometrial cancer, hematologic malignancies, and multiple myeloma, where, healthcare organizations provide patients with oncolytic virotherapy and develop potent, safe, and cost-effective cancer therapies in areas of unmet need.
Who invested in Vyriad
4 investors across 2 rounds
See all investors in Vyriad
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Vyriad
Who invested in Vyriad?
Vyriad has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Vyriad raised?
Vyriad has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Vyriad last raise money?
Vyriad's most recent round on record is a Series B, in May 2022.
What does Vyriad do?
Based in Minnesota, US, and founded in 2015 by Stephen J.
Where is Vyriad headquartered?
Vyriad is headquartered in US.
Which VCs invest in companies like Vyriad?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Vyriad's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Vyriad? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.